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ABSTRACT
Objective To summarise existing data on the 
relation between the time from symptom onset until 
revascularisation (time to reperfusion) and the myocardial 
salvage index (MSI) calculated as proportion of non- 
necrotic myocardium inside oedematous myocardium 
on T2- weighted and T1- weighted late gadolinium 
enhancement MRI after ST- segment elevation myocardial 
infarction (STEMI).
Methods Studies including patients with revascularised 
STEMI and stating both the time to reperfusion and 
the MSI measured by T2- weighted and T1- weighted 
late gadolinium enhancement MRI were searched in 
MEDLINE, EMBASE and ISI Web of Science until 16 
May 2020. A mixed effects model was used to evaluate 
the relation between the time to reperfusion and the 
MSI. The gender distribution and mean age in included 
patient groups, the timing of MRI, used MRI sequences 
and image interpretation methodology were included 
in the mixed effects model to explore between- study 
heterogeneity.
Results We included 38 studies with 5106 patients. 
The pooled MSI was 42.6% (95% CI: 38.1 to 47.1). The 
pooled time to reperfusion was 3.8 hours (95% CI: 3.5 to 
4.0). Every hour of delay in reperfusion was associated 
with an absolute decrease of 13.1% (95% CI: 11.5 to 
14.6; p<0.001) in the MSI. Between- study heterogeneity 
was considerable (σ2=167.8). Differences in the gender 
distribution, timing of MRI and image interpretation 
among studies explained 45.2% of the between- study 
heterogeneity.
Conclusions The MSI on T2- weighted and T1- weighted 
late gadolinium enhancement MRI correlates inversely 
with the time to reperfusion, which indicates that 
cardioprotection achieved by minimising the time to 
reperfusion leads to a higher MSI. The analysis revealed 
considerable heterogeneity between studies. The 
heterogeneity could partly be explained by differences 
in the gender distribution, timing and interpretation of 
MRI suggesting that the MRI- assessed MSI is not only 
influenced by cardioprotective therapy but also by patient 
characteristics and MRI parameters.
INTRODUCTION
Despite a rising incidence of myocardial 
infarction worldwide, a reduction in mortality 
has been observed in industrialised nations.1 
This reduction is attributable to salvage of 
myocardium by therapeutic reopening of 
culprit arteries using either percutaneous 
coronary intervention or fibrinolysis.2 
Salvaged myocardium is defined as the differ-
ence in size between the previously ischaemic 
area at risk distal to the obstructed coronary 
artery and the final infarct size.3 Quantifi-
cation of salvaged myocardium after revas-
cularisation therapy allows evaluation of 
therapeutic efficiency and can be used as an 
outcome parameter in studies that investigate 
cardioprotective strategies.3 99mTechnetium- 
sestamibi single- photon emission tomography 
(SPECT) is currently the reference standard 
for quantification of salvaged myocardium.3 
Unfortunately, there are several disadvantages 
that limit its use. SPECT involves radiation 
exposure and is logistically demanding since 
it requires constant availability of the tracer 
and requires two examinations at different 
points in time. The tracer has to be injected 
prior to revascularisation to measure the area 
Strengths and limitations of this study
 ► A comprehensive search in three electronic data-
bases was performed and a large number of studies 
could be included.
 ► State- of- the- art statistical tests for meta- regression 
analyses were applied.
 ► Data on T2- weighted and T1- weighted mapping MRI, 
which is a valuable and increasingly used alternative 
to conventional T2- weighted and T1- weighted late 
gadolinium enhancement MRI for quantifying oe-
dematous and fibrotic myocardium, are not included 
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at risk and 1 month after revascularisation to measure the 
final infarct size.3
MRI has been investigated as an alternative method to 
quantify salvaged myocardium that is logistically easier 
to perform, involves no radiation exposure, can be 
performed in a single examination3 and enables a unique 
integration of myocardial pathology and measures of 
myocardial function, such as myocardial strain.4 The 
widely accepted MRI techniques of T1- weighted late 
gadolinium enhancement for measuring necrotic tissue 
and T2- weighted MRI for identifying oedematous tissue5 
are combined and used to quantify salvaged myocardium 
based on the assumptions that myocardial necrosis on 
T1- weighted late gadolinium enhancement MRI can be 
used to delineate the final infarct size, and that myocar-
dial oedema on T2- weighted MRI can be used to delineate 
the previously ischaemic area at risk.6 However, the latter 
assumption has been a subject of controversial discus-
sion.7 8 While the results of some studies suggest that the 
area at risk can be delineated by measuring myocardial 
oedema on T2- weighted MRI,9–13 other studies contra-
dict these findings.14–19 A panel of experts in the field of 
postmyocardial infarction MRI recently concluded that 
oedema on MRI after myocardial infarction should be 
seen as manifestation of myocardial injury induced by 
ischemia and reperfusion rather than the previously isch-
aemic area at risk.20
The purpose of this meta- regression analysis was to 
summarise existing data on the relation between the 
time from symptom onset until revascularisation (time 
to reperfusion) and the myocardial salvage index (MSI) 
calculated as proportion of non- necrotic myocardium 
inside oedematous myocardium on T2- weighted and 
T1- weighted late gadolinium enhancement MRI after 
ST- segment elevation myocardial infarction (STEMI).
MATERIALS AND METHODS
Reporting of this systematic review and meta- regression 
analysis followed the Preferred Reporting Items for 
Systematic reviews and Meta- Analyses (PRISMA) 
guidelines.21
Inclusion and exclusion criteria, search strategy and data 
extraction
Included studies had to fulfil the following inclusion 
criteria: (1) STEMI in all study patients; (2) primary 
percutaneous intervention as part of emergency care; 
(3) reporting of the MSI calculated as proportion of non- 
necrotic myocardium inside oedematous myocardium on 
T2- weighted and T1- weighted late gadolinium enhance-
ment MRI in the first week after STEMI or alternatively 
reporting of the spatial extent of oedematous left ventric-
ular myocardium on T2- weighted MRI along with the 
spatial extent of left ventricular necrotic myocardium on 
T1- weighted late gadolinium enhancement MRI, which 
enabled calculation of the MSI; (4) application of a unit 
compatible to the percentage of the whole left ventricular 
myocardium for measuring oedema and necrosis on MRI 
(see online supplemental table 1); (5) reporting of CI, SD 
or IQR for the MSI or the spatial extents of myocardial 
oedema and necrosis on T2- weighted and T1- weighted 
late gadolinium enhancement MRI; (6) reporting of 
the time to reperfusion and (7) publication in English, 
German or French. Animal studies were excluded.
MEDLINE, EMBASE and ISI Web of Science were 
searched from inception until 16 May 2020. The search 
term for every database can be found in online supple-
mental file 1. Titles and abstracts of references found in 
the databases were screened before a full- text review was 
performed. The bibliography of included studies and 
reviews was screened for further eligible studies.
General information about the studies were extracted 
onto a predefined datasheet along with information on 
the time to reperfusion, MRI results, used MRI technique 
and basic patient characteristics.
The eligibility criteria and the search term were set up 
by two reviewers (BK and MD) and adjusted by discus-
sion in the research group on non- invasive cardiovascular 
imaging at Charité—Universitätsmedizin Berlin. BK and 
HS performed the database search, title and abstract 
review, full- text review and data extraction independently; 
discrepancies were resolved by discussion, if necessary 
together with MD.
Statistical analysis
If included studies did not state the MSI but the spatial 
extents of oedematous and necrotic myocardium 
measured by T2- weighted and T1- weighted late gado-
linium enhanced MRI, we calculated the MSI ourselves as 
the proportion of non- necrotic myocardium inside oedem-
atous myocardium on T2- weighted and T1- weighted late 
gadolinium enhancement MRI. The Delta Method was 
applied to estimate the variance andSD.22
To get an overview of the data, random effects models 
were applied to calculate pooled values for all extracted 
continuous variables: the MSI on T2- weighted and 
T1- weighted late gadolinium enhancement MRI, time to 
reperfusion, mean age and percent of male patients. The 
results of sub- groups within studies were included sepa-
rately when available. We did not consider these obser-
vations to be independent from each other because of 
similar study methods. The intercept was thus allowed 
to vary randomly for each study to account for multiple 
observations per study. Each patient group’s result was 
weighted by the inverse of its squared estimated SE. In 
case of the percent of male patients, the logit transfor-
mation was used to stabilise the variance and avoid a 
variance- on- mean relationship.23 Furthermore, we calcu-
lated frequency distributions for all extracted categorical 
variables: T2- weighted MRI sequence, T1- weighted late 
gadolinium enhancement MRI sequence, T2- weighted 
MRI interpretation method, T1- weighted late gadolinium 
enhancement MRI interpretation method and timing of 
MRI. The individual categories for each categorical vari-
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to be more stable in the time window between days 3 and 
7 after STEMI,20 and we thus categorised the timing of 
MRI into 1–2 days and 3–7 days after STEMI.
A mixed effects model was used to test for an associa-
tion between the time to reperfusion and the MSI. The 
MSI was used as a dependent variable. The time to reper-
fusion was used as fixed effect. Again, the intercept was 
allowed to vary randomly for each study to account for 
multiple observations per study. Between- study heteroge-
neity was evaluated using Cochran’s Q Test. We weighted 
each patient group’s result by the inverse of the squared 
estimated SE of the mean of the MSI. On request of the 
reviewers, the model was also calculated after excluding 
outlying patient groups having a mean time to perfusion 
of less than 2 hours.
To explore the between- study heterogeneity in the 
mixed effects model, basic patient characteristics and MRI 
parameters were included in the mixed effects model 
with the time to reperfusion as fixed effect and study as 
random effect. The mean age and gender distribution were 
included as continuous fixed effects, while the timing of 
MRI, T2- weighted MRI sequence, T1- weighted late gado-
linium enhancement MRI sequence, T2- weighted MRI 
interpretation method and T1- weighted late gadolinium 
enhancement MRI interpretation method were included 
as categorical fixed effects. Each of the variables was 
included separately in the mixed effects model. The like-
lihood ratio test was applied to test whether the included 
variable provided a significantly better fit. All significant 
confounding variables were included together in the mixed 
effects model. Interactions were not included to avoid over-
fitting. The unexplained between- study variance σ2 was 
compared between the hereby resulting model and the 
original model without inclusion of confounding variables.
Table 1 Basic characteristics of included study populations and MRI technique used by included studies
Basic characteristics of included study populations
Characteristic Pooled mean (95% CI)
Age, years 59.9 (95% CI: 59.0 to 60.7)
Male, % of patients 81.7 (95% CI: 79.3 to 83.9)
MRI technique used by included studies
Technical parameter % of included studies (n)
Timing of MRI
  3–7 days after STEMI 79% (30)
  1–2 days after STEMI 21% (8)
T2- weighted MRI sequence*
  T2- weighted dark- blood TSE/FSE with IR (STIR) 90% (34)
  T2- prepared bright- blood single- shot balanced SSFP 11% (4)
  Hybrid TSE- SSFP (ACUTE) 5% (2)
  BLADE k- space coverage for dark- blood TSE 3% (1)
T1- weighted late gadolinium enhancement MRI sequence
  PSIR using segmented FLASH readout (SPGR) 97% (37)
  IR with single- shot SSFP 3% (1)
T2- weighted MRI interpretation
  Signal intensity>2 SD above remote myocardium 66% (25)
  Manual contouring 29% (11)
  FWHM algorithm 5% (2)
T1- weighted late gadolinium enhancement MRI interpretation†
  Signal intensity>5 SD above remote myocardium 37% (14)
  Signal intensity>2 SD above remote myocardium 16% (6)
  Signal intensity>3 SD above remote myocardium 3% (1)
  Manual contouring 29% (11)
  FWHM algorithm 11% (4)
  Heiberg’s method 8% (3)
*One included study compared four T2- weighted MRI sequences.
†One included study applied two T1- weighted late gadolinium enhancement MRI interpretation methods.
ACUTE, acquisition for cardiac unified T2 oedema; FLASH, fast low angle shot; FSE, fast spin echo; FWHM, full width at half maximum; IR, inversion 
recovery; PSIR, phase- sensitive inversion recovery; SPGR, spoiled gradient echo; SSFP, steady- state free precession; STEMI, ST- segment elevation 
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We assumed statistical significance for p values of less 
than 0.05. We used R (V.3.6.0, 2019, R Foundation of Statis-
tical Computing) for the whole statistical analysis. The 
metafor R package was used to set up random and mixed 
effects models.24 Two reviewers (PS and BK) planned the 
statistical analysis, which was performed afterwards by BK. 
The results were regularly discussed with and checked by 
PS to assure accuracy. The final results were discussed 
in the research group on non- invasive cardiovascular 
imaging at Charité—Universitätsmedizin Berlin.
Risk of bias assessment
We applied the component approach25 for assessing the 
risk of bias in individual studies, and thus developed a 
set of items for the domains of bias we considered most 
relevant to this meta- analysis: selection bias, attrition bias 
and detection bias. The items are explained in detail in 
online supplemental table 2. The risk of publication bias 
was assessed across studies by searching for obvious asym-
metry in a funnel plot created with the data on the MSI. 
Begg and Mazumdar’s correlation test26 and Egger et al’s 
regression test27 were applied as additional tests for publi-
cation bias.
Patient and public involvement
No patients were involved in setting the research question 
or design of the study. No patients were asked to advise on 
the interpretation of the results. We aim to present the 
results of the study to a wide audience, including patients, 
health professionals and members of the public.
RESULTS
Study selection is summarised by the PRISMA flow chart 
in figure 1. We included 38 studies with 5106 patients 
in this meta- regression analysis.28–61 Eighteen studies 
calculated and reported the MSI as proportion of non- 
necrotic myocardium inside oedematous myocardium on 
T2- weighted and T1- weighted late gadolinium enhance-
ment MRI. For 19 studies, we calculated the MSI using 
available data on the spatial extent of oedematous and 
necrotic left ventricular myocardium on T2- weighted and 
T1- weighted late gadolinium enhancement MRI. Table 
1 summarises basic patient characteristics and the used 
MRI technique.
Figure 1 PRISMA flow chart; abstract and title review was performed of 1784 references that were found in MEDLINE, 
EMBASE and ISI Web of Science. We performed full- text review of 186 studies and included 38 studies in this meta- regression 
analysis. MSI, myocardial salvage index; PRISMA, Preferred Reporting Items for Systematic reviews and Meta- Analyses; 
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The pooled MSI was 42.6% (95% CI: 38.9 to 47.0). 
The pooled time to reperfusion was 3.8 (95% CI: 3.5 
to 4.0). There was an inverse correlation between the 
time to reperfusion and the MSI (figure 2). Every hour 
of delay in reperfusion was associated with an absolute 
decrease of 13.1% (95% CI: 11.5 to 14.6; p<0.001) in 
the MSI. Between- study heterogeneity was considerable 
(σ2=167.8). Details of the mixed effects model can be 
found in table 2. The results of the mixed effects model 
calculated after excluding two outlying patient groups 
with a mean time to perfusion of less than 2 hours are 
summarised in online supplemental table 3.
Including basic patient characteristics and MRI param-
eters separately in the mixed effects model revealed that 
the inclusion of the timing of MRI (χ2(1)=11.5, p<0.001), 
T2- weighted MRI interpretation method (χ2(2)=7.8, 
p=0.020), T1- weighted late gadolinium enhancement 
MRI interpretation method (χ2(5)=15.3, p=0.009) and 
gender distribution (χ2(1)=11.3, p<0.001) resulted in 
a significantly better fit of the mixed effects model, 
while the inclusion of the T2- weighted MRI sequence 
(χ2(3)=5.6, p=0.131), T1- weighted late gadolinium 
enhancement MRI sequence (χ2(1)=0.5, p=0.468) and 
mean age (χ2(1)<0.1, p=0.995) did not. Inclusion of all 
significant confounding variables in the mixed effects 
model reduced the between- study heterogeneity by 
45.2% to σ2=91.9. The detailed parameters of this model 
can be found in online supplemental table 4.
The risk of selection bias, attrition bias and detection 
bias in included studies is summarised in figure 3. The 
detailed judgements for every study can be found in 
online supplemental tables 5–7. We neither find evidence 
of publication bias across studies by searching for obvious 
asymmetry in the created funnel plot with the data on the 
MSI measured by MRI (see online supplemental figure 
1) nor by applying Begg and Mazumdar’s rank correla-
tion test (z=−1.4, p=0.173) and Egger et al’s regression test 
(t=0.7, p=0.507).
All raw data extracted from included studies can be 
found in online supplemental table 8.
DISCUSSION
This meta- regression analysis was conducted to summarise 
existing data on the relation between the time to reper-
fusion and the MSI on T2- weighted and T1- weighted late 
gadolinium enhancement MRI after STEMI. The analysis 
showed that a short delay between symptom onset and 
revascularisation is associated with a large MSI, while a 
long delay between symptom onset and revascularisa-
tion is associated with a small MSI. There is considerable 
heterogeneity between studies.
Comparison with other studies
We did not find a meta- analysis in MEDLINE, EMBASE, 
ISI Web of Science, Cochrane or PROSPERO that 
summarised data on the relation between the time to 
reperfusion and the MSI on T2- weighted and T1- weighted 
late gadolinium enhancement MRI after STEMI. While 
Figure 2 Inverse correlation between the time to reperfusion 
and the myocardial salvage index. The dashed lines represent 
the lower and upper 95% CI. The point size reflects the 
weight of a patient group, which was calculated as the 
inverse of the squared estimated SE. Time to reperfusion, 
time from symptom onset until revascularisation.





Factor σ2 σ Cochran’s Q Test 
for heterogeneity
P value
Study 167.8* 13.0* <0.001
Fixed effects




(intercept) 91.7 <0.001 84.5 98.9
Time to reperfusion, 
hours
−13.1 <0.001 −14.6 −11.5
*Exploration of heterogeneity: Separate inclusion of the timing 
of MRI (χ2(1)=11.5, p<0.001), T2- weighted MRI interpretation 
method (χ2(2)=7.8, p=0.020), T1- weighted late gadolinium 
enhancement MRI interpretation method (χ2(5)=15.3, p=0.009) 
and gender distribution (χ2(1)=11.3, p<0.001) resulted in a 
significantly better fit of the mixed effects model, while the 
inclusion of the T2- weighted MRI sequence (χ2(3)=5.6, p=0.131), 
T1- weighted late gadolinium enhancement MRI sequence 
(χ2(1)=0.5, p=0.468) and mean age (χ2(1)<0.1, p=0.995) did not. 
Inclusion of all significant confounding variables reduced the 
between- study heterogeneity by 45.2% to σ2=91.9 (see online 
supplemental table 4).
AIC, Akaike information criterion; BIC, Bayesian information 
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most of, in this meta- regression analysis, included 
studies did not primarily study the impact of revascular-
isation delay on the MSI measured by T2- weighted and 
T1- weighted late gadolinium enhancement MRI, Fran-
cone et al subcategorised study patients into four time to 
reperfusion intervals.40 Consistent with the main result of 
this meta- regression analysis, the data of Francone et al 
show an inverse correlation between the time to reper-
fusion and the MSI on T2- weighted and T1- weighted late 
gadolinium enhancement MRI.
As mentioned in the Introduction section, opin-
ions differ on whether measurement of the extent of 
myocardial oedema by T2- weighted MRI allows delinea-
tion of the previously ischaemic area at risk differ.7–19 In 
their landmark studies of the wavefront phenomenon 
of myocardial death, Reimer et al showed that necrotic 
myocardium gradually expands from the subendocar-
dium toward the subepicardium in the ischaemic area at 
risk as long as ischemia persists, while this expansion can 
be halted by revascularisation of the ischaemic area.62 63 
The gradual expansion of myocardial necrosis measured 
by T1- weighted late gadolinium enhancement MRI 
within infarction- induced myocardial oedema measured 
by T2- weighted MRI with increasing time to reperfu-
sion showed in this meta- analysis suggests a connection 
between the area at risk and the extent of myocardial 
oedema. However, the data cannot exclude underestima-
tion or overestimation of the area at risk using myocardial 
oedema on T2- weighted MRI, and therefore the conclu-
sion that myocardial oedema on T2- weighted MRI delin-
eates the area at risk cannot be made.
Meaning of the study and future perspective
Regardless of if myocardial oedema on T2- weighted MRI 
delineates the area at risk, underestimates or overestimates 
it, the gradual expansion of necrosis within infarction- 
induced oedema with increasing time to reperfusion 
indicates that measurement of the proportion of oedem-
atous myocardium without necrosis by T2- weighted and 
T1- weighted late gadolinium enhancement MRI might 
be of use for evaluating therapeutic efficiency, which 
may be helpful for studies investigating cardioprotective 
strategies.
The heterogeneity between studies suggests that other 
factors different from the time to reperfusion affect 
the proportion of oedematous myocardium without 
necrosis measured by T2- weighted and T1- weighted late 
gadolinium enhancement MRI after myocardial infarc-
tion. Since the heterogeneity analysis revealed signifi-
cant confounding effects for the timing of imaging and 
image interpretation, differences in MRI methodologies 
should be resolved in the future to improve compara-
bility of the results. The need for a standardisation of 
postmyocardial infarction MRI methodologies has also 
recently been highlighted by experts in the field.20 The 
use of T2- mapping and T1- mapping MRI, which is a valu-
able and increasingly used alternative to conventional 
T2- weighted and T1- weighted late gadolinium enhance-
ment MRI, may be a step forward in this regard since it 
allows a less subjective and more consistent delineation 
of oedematous and fibrotic myocardium.64 The hetero-
geneity analysis furthermore suggests that gender differ-
ences should be considered when interpreting the MSI, 
which has previously been described as well.65 66 Differ-
ences in cardioprotective strategies apart from the time 
to reperfusion may explain a fraction of the remaining 
heterogeneity.43 57 Further research on the factors influ-
encing the MSI measured by MRI is needed before a reli-
able evaluation of therapy efficiency may be possible by 
measuring the MSI with MRI.
Strengths and limitations
This systematic review and meta- regression analysis 
has methodological strengths. Reporting followed the 
PRISMA guidelines.21 After a comprehensive search in 
three electronic databases, a large number of studies 
could be included. State- of- the- art statistical tests for meta- 
regression analyses were applied for data analysis. We did 
not register a review protocol a priori, which increased 
the likelihood of our post hoc decisions to be biassed.21 
Last, data on T2- mapping and T1- mapping MRI are not 
included in this meta- regression analysis. As mentioned 
above, mapping MRI may overcome inconsistencies when 
delineating the extent of myocardial oedema and fibrosis; 
however, only a few studies already applied mapping 
MRI for measuring the MSI. To have enough data for a 
conclusive meta- regression analysis, we therefore decided 
to search and include studies that used conventional 
T2- weighted and T1- weighted late gadolinium enhance-
ment MRI.
CONCLUSIONS
The MSI calculated as proportion of non- necrotic myocar-
dium inside oedematous myocardium on T2- weighted 
and T1- weighted late gadolinium enhancement MRI after 
revascularisation in STEMI correlates inversely with the 
time to reperfusion, which indicates that cardioprotection 
Figure 3 Risk of bias in individual studies. The risk of 
selection bias was judged as low in 25 of 34 studies, attrition 
bias in 34 studies and detection bias in 28 studies. In one 
study, the risk of selection bias was judged as high, and in 
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achieved by minimising the time to reperfusion leads to 
a higher MSI measured by MRI. The analysis revealed 
considerable heterogeneity between studies. A substantial 
part of the heterogeneity could be explained by differ-
ences in the gender distribution, timing and interpreta-
tion of MRI suggesting that the MRI- assessed MSI is not 
only influenced by cardioprotective therapy but also by 
patient characteristics and MRI parameters. One reviewer 
performed the database search, data extraction and statis-
tical analysis, which limits the results.
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